JP2023010979A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023010979A5 JP2023010979A5 JP2022187561A JP2022187561A JP2023010979A5 JP 2023010979 A5 JP2023010979 A5 JP 2023010979A5 JP 2022187561 A JP2022187561 A JP 2022187561A JP 2022187561 A JP2022187561 A JP 2022187561A JP 2023010979 A5 JP2023010979 A5 JP 2023010979A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- ala
- core sequence
- seq
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 34
- 102000004196 processed proteins & peptides Human genes 0.000 claims 29
- 108090000765 processed proteins & peptides Proteins 0.000 claims 29
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 claims 14
- 206010061218 Inflammation Diseases 0.000 claims 11
- 230000004054 inflammatory process Effects 0.000 claims 11
- 125000000539 amino acid group Chemical group 0.000 claims 8
- QWCKQJZIFLGMSD-UHFFFAOYSA-N 2-Aminobutanoic acid Natural products CCC(N)C(O)=O QWCKQJZIFLGMSD-UHFFFAOYSA-N 0.000 claims 7
- UBXUDSPYIGPGGP-UHFFFAOYSA-N 2-azaniumyl-2-phenylbutanoate Chemical compound CCC(N)(C(O)=O)C1=CC=CC=C1 UBXUDSPYIGPGGP-UHFFFAOYSA-N 0.000 claims 7
- OFYAYGJCPXRNBL-UHFFFAOYSA-N 2-azaniumyl-3-naphthalen-1-ylpropanoate Chemical compound C1=CC=C2C(CC(N)C(O)=O)=CC=CC2=C1 OFYAYGJCPXRNBL-UHFFFAOYSA-N 0.000 claims 7
- QWCKQJZIFLGMSD-GSVOUGTGSA-N D-alpha-aminobutyric acid Chemical compound CC[C@@H](N)C(O)=O QWCKQJZIFLGMSD-GSVOUGTGSA-N 0.000 claims 7
- UQBOJOOOTLPNST-UHFFFAOYSA-N Dehydroalanine Chemical compound NC(=C)C(O)=O UQBOJOOOTLPNST-UHFFFAOYSA-N 0.000 claims 7
- -1 β-cyclohexyl-Ala Chemical compound 0.000 claims 7
- 150000001413 amino acids Chemical class 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- 238000001990 intravenous administration Methods 0.000 claims 3
- 238000007920 subcutaneous administration Methods 0.000 claims 3
- 230000000699 topical effect Effects 0.000 claims 3
- 206010028116 Mucosal inflammation Diseases 0.000 claims 2
- 201000010927 Mucositis Diseases 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 101000979342 Homo sapiens Nuclear factor NF-kappa-B p105 subunit Proteins 0.000 claims 1
- 102100023050 Nuclear factor NF-kappa-B p105 subunit Human genes 0.000 claims 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 1
- 208000019622 heart disease Diseases 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000026731 phosphorylation Effects 0.000 claims 1
- 238000006366 phosphorylation reaction Methods 0.000 claims 1
- 230000034190 positive regulation of NF-kappaB transcription factor activity Effects 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462055982P | 2014-09-26 | 2014-09-26 | |
| US62/055,982 | 2014-09-26 | ||
| JP2021036502A JP7184946B2 (ja) | 2014-09-26 | 2021-03-08 | 疾患及び障害の治療のためのｎｆカッパｂ活性の阻害剤 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021036502A Division JP7184946B2 (ja) | 2014-09-26 | 2021-03-08 | 疾患及び障害の治療のためのｎｆカッパｂ活性の阻害剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023010979A JP2023010979A (ja) | 2023-01-20 |
| JP2023010979A5 true JP2023010979A5 (enExample) | 2023-05-29 |
Family
ID=55582262
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017516948A Active JP6851965B2 (ja) | 2014-09-26 | 2015-09-25 | 疾患及び障害の治療のためのｎｆカッパｂ活性の阻害剤 |
| JP2021036502A Active JP7184946B2 (ja) | 2014-09-26 | 2021-03-08 | 疾患及び障害の治療のためのｎｆカッパｂ活性の阻害剤 |
| JP2022187561A Pending JP2023010979A (ja) | 2014-09-26 | 2022-11-24 | 疾患及び障害の治療のためのｎｆカッパｂ活性の阻害剤 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017516948A Active JP6851965B2 (ja) | 2014-09-26 | 2015-09-25 | 疾患及び障害の治療のためのｎｆカッパｂ活性の阻害剤 |
| JP2021036502A Active JP7184946B2 (ja) | 2014-09-26 | 2021-03-08 | 疾患及び障害の治療のためのｎｆカッパｂ活性の阻害剤 |
Country Status (7)
| Country | Link |
|---|---|
| US (5) | US10030048B2 (enExample) |
| EP (1) | EP3197474B1 (enExample) |
| JP (3) | JP6851965B2 (enExample) |
| CN (2) | CN106999535B (enExample) |
| AU (2) | AU2015320341B2 (enExample) |
| CA (1) | CA2999711A1 (enExample) |
| WO (1) | WO2016049580A2 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3197474B1 (en) | 2014-09-26 | 2023-06-07 | Rajendra Sahai Bhatnagar | Inhibitors of nf kappa-b activity for treatment of diseases and disorders |
| US9943566B2 (en) | 2016-03-16 | 2018-04-17 | Geoffrey Brooks Consultants, Llc | NF-κB inhibitor composition for skin health |
| US20220133837A1 (en) * | 2020-08-28 | 2022-05-05 | Rajendra Sahai Bhatnagar | Peptide inhibitors of nf kappa b and use thereof in treatment of covid-19 and inflammatory diseases |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1991000916A2 (en) * | 1989-07-06 | 1991-01-24 | The Regents Of The University Of California | Receptors for fibroblast growth factors |
| US5674848A (en) | 1989-08-14 | 1997-10-07 | The Regents Of The University Of California | Bioreactor compositions with enhanced cell binding |
| US20030077825A1 (en) | 1994-07-22 | 2003-04-24 | Bhatnagar Rajendra S. | Structures useful for bone engineering and methods |
| US5354736A (en) | 1989-08-14 | 1994-10-11 | Regents Of The University Of California | Synthetic compounds and compositions with enhanced cell binding |
| US5635482A (en) | 1989-08-14 | 1997-06-03 | The Regents Of The University Of California | Synthetic compounds and compositions with enhanced cell binding |
| EP0487617B1 (en) | 1989-08-14 | 1996-10-02 | The Regents Of The University Of California | Synthetic peptides that enhance cell binding |
| WO1995016709A2 (en) * | 1993-12-13 | 1995-06-22 | Biogen, Inc. | Anti-mullerian hormone receptor polypeptides and antibodies thereto |
| US6638912B2 (en) | 1995-05-01 | 2003-10-28 | The Regents Of The University Of California | Peptide compositions mimicking TGF-β activity |
| US5780436A (en) | 1995-05-01 | 1998-07-14 | The Regents Of The University Of California | Peptide compositions with growth factor-like activity |
| US5661127A (en) * | 1995-05-01 | 1997-08-26 | The Regents Of The University Of California | Peptide compositions with growth factor-like activity |
| WO1998009620A1 (en) * | 1996-09-05 | 1998-03-12 | Research Development Foundation | INHIBITION OF NUCLEAR TRANSCRIPTION FACTOR NF-λB BY CAFFEIC ACID PHENETHYL ESTER (CAPE), DERIVATIVES OF CAPE, CAPSAICIN (8-METHYL-N-VANILLYL-6-NONENAMIDE) AND RESINIFERATOXIN |
| US6197586B1 (en) | 1997-12-12 | 2001-03-06 | The Regents Of The University Of California | Chondrocyte-like cells useful for tissue engineering and methods |
| US6864355B1 (en) | 2000-05-02 | 2005-03-08 | Yale University | Inhibition of NF-κB activation by blockade of IKKβ-NEMO interactions at the NEMO binding domain |
| DE19951360A1 (de) * | 1999-10-26 | 2001-05-03 | Aventis Pharma Gmbh | Substituierte Indole |
| WO2001082773A2 (en) | 2000-04-28 | 2001-11-08 | The Regents Of The University Of California | Structures useful for bone engineering and methods |
| US6509318B1 (en) * | 2000-09-29 | 2003-01-21 | The Regents Of The University Of California | TGF-B inhibitors and methods |
| AUPR279101A0 (en) * | 2001-01-30 | 2001-02-22 | Cytopia Pty Ltd | Protein kinase signalling |
| JP4943848B2 (ja) * | 2003-10-07 | 2012-05-30 | イエダ リサーチ アンド ディベロップメント カンパニー リミテッド | Ｎｉｋに対する抗体、その調製および使用 |
| US20060211075A1 (en) * | 2005-03-02 | 2006-09-21 | The Albert Einstein College Of Medicine Of Yeshiva University | Enzyme sensors including environmentally sensitive or fluorescent labels and uses thereof |
| US20070009568A1 (en) | 2005-06-03 | 2007-01-11 | Bhatnagar Rajendra S | Methods for immobilizing molecules on surfaces |
| US20060293227A1 (en) | 2005-06-24 | 2006-12-28 | Bhatnagar Rajendra S | Cosmetic compositions and methods using transforming growth factor-beta mimics |
| US20060293228A1 (en) * | 2005-06-24 | 2006-12-28 | Bhatnagar Rajendra S | Therapeutic compositions and methods using transforming growth factor-beta mimics |
| EP2150273A4 (en) | 2007-04-27 | 2010-11-17 | Univ Toledo | MODIFIED PLASMINOGEN ACTIVATOR INHIBITOR MOLECULE AND METHODS OF USE |
| WO2009013753A1 (en) * | 2007-07-24 | 2009-01-29 | Thrombotech Ltd. | Peptides derived from plasminogen activator inhibitor-1 and uses thereof |
| CA2695374A1 (en) * | 2007-08-15 | 2009-02-19 | Amunix, Inc. | Compositions and methods for modifying properties of biologically active polypeptides |
| EP2124060A1 (en) * | 2008-05-23 | 2009-11-25 | ETH Zurich | Method for high throughput peptide/protein assay generation and assays generated therewith |
| WO2009152610A1 (en) | 2008-06-20 | 2009-12-23 | The Royal Institution For The Advancement Of Learning/Mcgill University | Interleukin-2/soluble tgf-beta type ii receptor b conjugates and methods and uses thereof |
| WO2010051064A1 (en) * | 2008-10-30 | 2010-05-06 | The Trustees Of Columbia University In The City Of New York | COMPOUNDS THAT INHIBIT NFκB ACTIVITY |
| US8614186B2 (en) * | 2009-05-27 | 2013-12-24 | Dana-Farber Cancer Institute, Inc. | Inhibition of inflammation using antagonists of MUC1 |
| CA2785038A1 (en) * | 2009-12-22 | 2011-07-21 | Stryker Corporation | Bmp-7 variants with reduced immunogenicity |
| JP2013176368A (ja) * | 2012-02-28 | 2013-09-09 | Oncotherapy Science Ltd | Ｖｅｇｆｒ２由来ペプチドおよびそれを含むワクチン |
| CN103223175B (zh) * | 2013-05-23 | 2015-07-22 | 中国人民解放军第三军医大学第三附属医院 | 抗瘢痕和组织纤维化寡聚双链核苷酸药物及其应用 |
| US20160000682A1 (en) | 2014-07-02 | 2016-01-07 | Geoffrey Brooks Consultants Llc | Peptide-Based Compositions and Methods of Use |
| EP3197474B1 (en) | 2014-09-26 | 2023-06-07 | Rajendra Sahai Bhatnagar | Inhibitors of nf kappa-b activity for treatment of diseases and disorders |
| US9943566B2 (en) | 2016-03-16 | 2018-04-17 | Geoffrey Brooks Consultants, Llc | NF-κB inhibitor composition for skin health |
| DE202018003082U1 (de) | 2018-07-03 | 2019-10-07 | Ergon International Gmbh | Fahrradsattel |
| US20220133837A1 (en) | 2020-08-28 | 2022-05-05 | Rajendra Sahai Bhatnagar | Peptide inhibitors of nf kappa b and use thereof in treatment of covid-19 and inflammatory diseases |
-
2015
- 2015-09-25 EP EP15844064.4A patent/EP3197474B1/en active Active
- 2015-09-25 CA CA2999711A patent/CA2999711A1/en active Pending
- 2015-09-25 JP JP2017516948A patent/JP6851965B2/ja active Active
- 2015-09-25 AU AU2015320341A patent/AU2015320341B2/en active Active
- 2015-09-25 CN CN201580064157.3A patent/CN106999535B/zh active Active
- 2015-09-25 WO PCT/US2015/052467 patent/WO2016049580A2/en not_active Ceased
- 2015-09-25 US US14/866,040 patent/US10030048B2/en active Active
- 2015-09-25 CN CN202111512016.7A patent/CN114432423B/zh active Active
-
2018
- 2018-05-17 US US15/982,837 patent/US11174286B2/en active Active
-
2021
- 2021-03-08 JP JP2021036502A patent/JP7184946B2/ja active Active
- 2021-08-25 AU AU2021221579A patent/AU2021221579B2/en active Active
- 2021-10-19 US US17/505,544 patent/US11773135B2/en active Active
-
2022
- 2022-11-24 JP JP2022187561A patent/JP2023010979A/ja active Pending
-
2023
- 2023-08-22 US US18/453,807 patent/US12325760B2/en active Active
-
2025
- 2025-05-13 US US19/206,572 patent/US20260015386A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102718858B (zh) | 胰高血糖素样肽-1类似物单体、二聚体及其制备方法与应用 | |
| JP2021091728A5 (enExample) | ||
| EP0235205B1 (en) | Peptide analogues of mammalian insulin-like growth factor-1 | |
| JP2002504112A (ja) | 上部胃腸管の安全性を高めるためのフィルムコーティング錠 | |
| EP0536741A2 (en) | Cyclic VIP analogs | |
| US5386011A (en) | Hexapeptide anaphylatoxin-receptor ligands | |
| JPH0680079B2 (ja) | ポリペプチド | |
| JP2025166240A5 (enExample) | ||
| JP3250804B2 (ja) | 治療用ペプチド | |
| US5387671A (en) | Hexa- and heptapeptide anaphylatoxin-receptor ligands | |
| HUT61036A (en) | Process for producing new polypeptides capable of linking to lipopolysaccharides and pharmaceutical compositions comprising same as active ingredients | |
| CN1917898B (zh) | 用于治疗间质肺部感染的血管活性肠肽的生物活性物质 | |
| PT94702B (pt) | Processo de preparacao de peptidos hemorreguladores | |
| DE69430295T2 (de) | Pulver zur nasalen Verabreichung peptidischer oder proteinischer Arzneistoffe | |
| Deunas et al. | Use of interferon-α in laryngeal papillomatosis: eight years of the Cuban national programme | |
| JP2018500274A5 (enExample) | ||
| AU2016255690B2 (en) | Pharmaceutical compound | |
| JP2022121359A5 (enExample) | ||
| US4263282A (en) | LH-RH-Peptides as contraceptives | |
| CA2465667A1 (en) | New peptides - analogs of human growth hormone-releasing hormone | |
| JP2022518527A5 (enExample) | ||
| JPS60161999A (ja) | ペプチド | |
| US12522642B2 (en) | Recombinant protein comprising multiple multi-peptide sets, pharmaceutical composition comprising the recombinant protein, and method for preparing the recombinant protein | |
| CN116370609A (zh) | 包含血管活性肠肽和吸收增强剂的固体组合物 | |
| CA2188143A1 (en) | Use of brain natriuretic peptides (bnp), phosphorylated urodilatine, phosphorylated cdd/anp and combinations thereof |